Tae Hyun Kang
Overview
Explore the profile of Tae Hyun Kang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
639
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim J, Lee A, Moon D, Chung Y, Hong S, Cho H, et al.
Emerg Microbes Infect
. 2024 Apr;
13(1):2343910.
PMID: 38618740
Japanese encephalitis (JE), caused by the Japanese encephalitis virus (JEV), is a highly threatening disease with no specific treatment. Fortunately, the development of vaccines has enabled effective defense against JE....
2.
Kim N, Kang S, Park G, Shim G, Kang T, Yu Y
Protein Sci
. 2022 Nov;
32(1):e4520.
PMID: 36419382
G protein-coupled receptors (GPCRs) are in the spotlight as drug targets due to the fact that multiple research results have verified the correlation between the activation of GPCRs and disease...
3.
Kim J, Lee J, Kim H, Kwak M, Kang T
Int J Mol Sci
. 2021 Sep;
22(17).
PMID: 34502398
The fragment crystallizable (Fc) domain of antibodies is responsible for their protective function and long-lasting serum half-life via Fc-mediated effector function, transcytosis, and recycling through its interaction with Fc receptors...
4.
Kang T, Seong B
Front Microbiol
. 2020 Oct;
11:1927.
PMID: 33101218
Solubility of recombinant proteins (i.e., the extent of soluble versus insoluble expression in heterogeneous hosts) is the first checkpoint criterion for determining recombinant protein quality. However, even soluble proteins often...
5.
Lee J, Der B, Karamitros C, Li W, Marshall N, Lungu O, et al.
AIChE J
. 2020 Apr;
66(3).
PMID: 32336757
We used the molecular modeling program Rosetta to identify clusters of amino acid substitutions in antibody fragments (scFvs and scAbs) that improve global protein stability and resistance to thermal deactivation....
6.
Kang T, Jung S
Biomolecules
. 2020 Mar;
10(3).
PMID: 32121592
The constant region of immunoglobulin (Ig) G antibodies is responsible for their effector immune mechanism and prolongs serum half-life, while the fragment variable (Fv) region is responsible for cellular or...
7.
Lee C, Kang T, Godon O, Watanabe M, Delidakis G, Gillis C, et al.
Nat Commun
. 2019 Nov;
10(1):5461.
PMID: 31767870
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
8.
Kang T, Jung S
Exp Mol Med
. 2019 Nov;
51(11):1-9.
PMID: 31735912
Monoclonal antibodies (mAbs) are one of the most widely used drug platforms for infectious diseases or cancer therapeutics because they selectively target pathogens, infectious cells, cancerous cells, and even immune...
9.
Lee C, Kang T, Godon O, Watanabe M, Delidakis G, Gillis C, et al.
Nat Commun
. 2019 Nov;
10(1):5031.
PMID: 31695028
The pharmacokinetic properties of antibodies are largely dictated by the pH-dependent binding of the IgG fragment crystallizable (Fc) domain to the human neonatal Fc receptor (hFcRn). Engineered Fc domains that...
10.
Kang T, Lee C, Delidakis G, Jung J, Goff O, Lee J, et al.
Front Immunol
. 2019 Apr;
10:562.
PMID: 30984171
IgG antibodies mediate the clearance of target cells via the engagement of Fc gamma receptors (FcγRs) on effector cells by eliciting antibody-dependent cellular cytotoxicity and phagocytosis (ADCC and ADCP, respectively)....